

American Society for Nanomedicine 5th Annual Meeting

Translational Nanomedicine: New solutions to Address Unmet Medical Needs

Registration and Societal Details: <https://amsocnanomed.org/>

Location: Hilton Crystal City, 2399 Jefferson Davis Hwy, Arlington, VA 22202
(Near Washington National Airport)

Dates: October 15 to 17, 2015

This year's ASNM annual meeting will highlight innovative applications of nanotechnology in both preclinical and clinical settings with special emphasis on translational nanomedicine. Workshops & educational sessions will offer guidance for scientists facing business, legal, and regulatory issues while translating their research findings into clinical applications. Ample opportunities will be provided for networking and interactions with leaders in the field and among the participants. Another highlight of the conference will be a session on nanomedicine's role in addressing the challenges of infectious diseases in global health.

In addition to the speakers listed below, posters will be submitted by graduate and post-doctoral trainees and those judged to be among the top four will receive awards on Saturday. Friday and Saturday, during an optional breakfast, "Meet-the-Expert" discussions will be held on a variety of topics geared to address questions and issues of young faculty, trainees, and anyone else. Friday noon a box lunch will be provided as part of the registration, and, participants may choose to attend an open audience Q&A session addressing business translational issues, which is followed by the Saturday AM session when speakers will talk about in more detail about these important topics.

To enhance inter-lab communication and networking, attendees are encouraged to provide a poster describing the research interests of the lab. These posters will be available for review throughout the meeting. They will also be projected in the meeting room before and during breaks as a continuous display changing about every 10 seconds or so to facilitate an appreciation for the research pursued in our different labs and to enhance interaction and collaboration.

Thursday PM

Opening Session

TOPIC: Nanomedicine Approaches to Vaccines and Anti-microbials

Nanoparticle Vaccines; Shaping the Immune Response

Keynote Speaker - James Baker, Jr. M.D., Ruth Dow Doan Professor of Biologic Nanotechnology, Professor Emeritus of Internal Medicine and Biomedical Engineering, University of Michigan

Title pending.

Danilo Casimiro Ph.D., Executive Director, Department of Viral Vaccine Research, Merck Research Laboratories, Merck & Co

Tolerogenic nanoparticles for the prevention of anti-drug antibodies and the treatment of autoimmune disease

Takashi Kei Kishimoto, Ph.D., Chief Scientific Officer, Selecta Biosciences, Inc.

Attacking Leishmania, a protozoan parasite ravaging 12 million patients in poverty, with nanotechnology

Gul Shahnaz, Ph.D., Department of Pharmacy, Faculty of Biological Sciences, Quaid-I-Azam University, Islamabad, Pakistan. Pakistan-US Science and Technology Cooperation Program and an UNESCO awardee

Long-acting cell targeted nanoformulated anti-retroviral therapy

Benson Edagwa Ph.D., Assistant Professor, Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center

Friday AM

TOPIC: Next Generation Preclinical Nanomedicine

A CRISPR look at gene editing: using CRISPR/Cas9 technology to make genetically modified cell lines and model organisms.

Shondra M. Pruett-Miller, Ph.D., Director of the Genomic Engineering and iPSC Center at Washington University School of Medical, Saint Louis, MO

Interactions between tumor microenvironment factors and nanomedicines influence efficacy

William Zamboni, PharmD. Ph.D., Associate Professor, Division of Pharmacotherapy and Experimental Therapeutics in the Eshelman School of Pharmacy and Molecular Therapeutics in the Lineberger Comprehensive Cancer Center, University of North Carolina

Targeted image-guided therapy of pancreatic cancer with stroma breaking nanoparticles

Lily Yang, M.D. Ph.D., Professor of Surgery and Nancy Panoz Chair of Surgery in Cancer Research, Department of Surgery, Emory University School of Medicine

Treatment of glioblastoma using a nanochain particle system

Stathis Karathanasis, Ph.D., Assistant Professor of Biomedical Engineering and Radiology Director of the Cancer Nanotechnology Lab, Department of Biomedical Engineering, Case Western Reserve University

Breaking the depth dependency of phototherapy with Cerenkov radiation and low-radiance-responsive nanophotosensitizers

Samuel Achilefu Ph.D., Director of Optical Radiology Lab, Professor of Radiology, Biochemistry & Molecular Biophysics and Biomedical Engineering, Department of Radiology, Washington University School of Medicine

Addressing the need for nanomedicines targeting hydrophobic compounds

Gert Storm, Ph.D., Professor of targeted drug delivery at the University of Utrecht and Professor of targeted therapeutics at the MIRA institute of the University of Twente.

Friday Afternoon

TOPIC: Clinical Translation of Nanomedicines

Keynote and Lifetime Achievement Award

Effective Translation of Innovative Medicinal Products: Understanding the Landscape, Asking the Right Questions, and Use of Robust Scientific Methodology

Ruth Duncan, Ph.D., Professor Emerita, prior Director of the Centre for Polymer Therapeutics at the Welsh School of Pharmacy, Cardiff University, UK

NCI Alliance for Nanotechnology in Cancer - a Model for Stimulating Transitions from Academic Research to Clinical Applications

Piotr Grodzinski, Ph.D., Director NCI Office of Cancer Nanotechnology Research, National Institute of Health

The NanoTherm Therapy – Fighting Cancer with Nanotechnology

Hoda Tawfik, M.D. Ph.D., Chief Medical Officer and Chief Operating Officer for Therapy Development, MagForce AG.

Development of liposome-based cancer nanomedicines - DOXIL and beyond

Alberto A. Gabizon, M.D. Ph.D., Director, Oncology Institute, Shaare Zedek Medical Center, and Professor of Oncology, The Hebrew University of Jerusalem; President and Founder, LipoMedix Pharmaceuticals.

New Developments in Targeted Gold Nanomedicines

Steven K. Libutti, M.D., Professor and Vice Chair, Department of Surgery, Associate Director for Clinical Services of the Albert Einstein Cancer Center, Albert Einstein College of Medicine

Translation of an effective cancer nanomedicine: is a targeting moiety truly necessary?

Esther H. Chang, Ph.D., Professor, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center ND and Founder of SynerGene

Ultras-small Dual-Modality C dots as Image-Guided Therapeutic Platforms for Oncology

Michelle Bradbury, M.D. Ph.D., Director, Intraoperative Imaging, Member, Molecular Pharmacology and Chemistry Program, and Associate Professor of Radiology, Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center

Saturday AM

TOPIC: Enabling the Business side of translation

Overview (IP, FDA, regulatory, critical current related issues)

Raj Bawa, M.S., Ph.D., Patent Agent, Bawa Biotech LLC (Ashburn, VA)
Adjunct Professor of Biological Sciences, Rensselaer Polytechnic Institute (Troy, NY)

Translational Pipeline to the Clinic – Navigating Key Challenges and Regulatory Guidances

Michelle Bradbury M.D., Ph.D., Associate Member, Memorial Sloan Kettering Cancer Center (New York, NY) Associate Professor of Radiology, Weill Medical College of Cornell University (New York, NY), and **Ulrich Wiesner, Ph.D.**, Spencer T. Olin Professor of Engineering,

Department of Materials, Science & Engineering, Cornell University (Ithaca, NY), Co-founders, Claymore Technologies

Patent Issues for an Academic Inventor – What, Why and How?

Brian Reese Ph.D., J.D., M.B.A., Associate, Choate, Hall & Stewart LLP (Boston, MA)

Roadmap to the Clinic – What, Why and How in Nanotox Assessment?

János Szebeni, M.D., Ph.D., D.Sc. Professor of Nanobiotechnology, Miskolc University (Budapest, Hungary); Professor and Head, Nanomedicine Research and Education Center Semmelweis University School of Medicine (Budapest, Hungary)

Licensing Medical Intellectual Property – What, Why and How?

Annette I. Kahler, J.D., Senior Counsel, Heslin Rothenberg Farley & Mesiti PC (Albany, NY)

AWARDS and Best Poster Presentations

2015 Conference Chair:

Gregory Lanza, M.D., Ph.D.

American Society for Nanomedicine Board of Directors:

Esther Chang, Ph.D., President & Founding Director

Raj Bawa, Ph.D., Secretary & Founding Director

Kuan Wang, Ph.D.

Marianna Foldvari, DPharm Sci. Ph.D.

Lajos P. Balogh, Ph.D.

Michelle Bradbury, M.D. Ph.D.

Wah Chiu, Ph.D.

Omid Farokhzad, M.D.

Howard E. Gendelman, M.D.

Gary Harris, Ph.D. P.E.

Gregory Lanza, M.D. Ph.D.